The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland

European Journal of Pain

Volumn 13, Issue 4, 2009, Pages 331-338

  Davies, Andrew N ^a   Dickman, Andrew ^b   Reid, Colette ^c   Stevens, Anna Marie ^a   Zeppetella, Giovambattista ^d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Marie Curie Palliative Care Institute   (United Kingdom)

^c GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d St Clare Hospice   (United Kingdom)

Author keywords

Breakthrough pain; Cancer; Pain; Palliative care

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; FENTANYL CITRATE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; SPASMOLYTIC AGENT;

BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE TITRATION; EVIDENCE BASED PRACTICE; HUMAN; INTERVENTIONAL RADIOLOGY; IRELAND; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; TRANSCUTANEOUS NERVE STIMULATION; UNITED KINGDOM;

ANALGESIA; ANALGESICS; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTRIC STIMULATION THERAPY; HUMANS; NEOPLASMS; NEUROSURGICAL PROCEDURES; PAIN CLINICS; PAIN MEASUREMENT; PAIN, INTRACTABLE; SELF ADMINISTRATION;

EID: 61849093095     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2008.06.014     Document Type: Review

References (58)

1. Bailey F., and Farley A. Oral opioid drugs. In: Davies A. (Ed). Cancer-related breakthrough pain (2006), Oxford University Press, Oxford 43-55
2. Bennett D., Burton A.W., Fishman S., Fortner B., McCarberg B., Miaskowski C., et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: Management. Pharm Therap 30 (2005) 354-361
3. Bruera E., Fainsinger R., MacEachern T., and Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 50 (1992) 75-77
4. Bruera E., Schoeller T., Wenk R., MacEachern T., Marcelino S., Hanson J., et al. A prospective multicenter assessment of the Edmonton Staging System for cancer pain. J Pain Sympt Manage 10 (1995) 348-355
5. Burton A.W., Reddy S.K., Shah H.N., Tremont-Lukats I., and Mendel E. Percutaneous vertebroplasty - a technique to treat refractory spinal pain in the setting of advanced metastatic cancer: a case series. J Pain Sympt Manage 30 (2005) 87-95
6. Carr D.B., Goudas L.C., Denman W.T., Brookoff D., Staats P.S., Brennan L., et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 108 (2004) 17-27
7. Christelis N., and Filshie J. Other therapeutic interventions. In: Davies A. (Ed). Cancer-related breakthrough pain (2006), Davies, Oxford 97-110
8. Christie J.M., Simmonds M., Patt R., Coluzzi P., Busch M.A., Nordbrock E., et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16 (1998) 3238-3245
9. Coluzzi P.H., Schwartzberg L., Conroy Jr. J.D., Charapata S., Gay M., Busch M.A., et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91 (2001) 123-130
10. Dale O. Opioid drugs via other routes. In: Davies A. (Ed). Cancer-related breakthrough pain (2006), Oxford University Press, Oxford 73-82
11. Davies A. Current thinking in cancer breakthrough pain management. Eur J Palliat Care 12 Suppl. (2005) 4-6
12. Davies A. Introduction. In: Davies A. (Ed). Cancer-related breakthrough pain (2006), Oxford University Press, Oxford 1-11
13. Davies A. General principles of management. In: Davies A. (Ed). Cancer-related breakthrough pain (2006), Oxford University Press, Oxford 31-42
14. Davies A.N., Vriens J., Kennett A., and McTaggart M. An observational study of oncology patients' utilisation of breakthrough pain medication. J Pain Sympt Manage 35 4 (2008) 406-411
15. del Rosario M.A., Martin A.S., Ortega J.J., and Feria M. Temporary sedation with midazolam for control of severe incident pain. J Pain Sympt Manage 21 (2001) 439-442
16. Enting R.H., Oldenmenger W.H., van der Rijt C.C., Wilms E.B., Elfrink E.J., Elswijk I., et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer 94 (2002) 3049-3056
17. Enting R.H., Mucchiano C., Oldenmenger, et al. The "pain pen" for breakthrough cancer pain: a promising treatment. J Pain Sympt Manage 29 (2005) 213-217
18. Farquhar-Smith P. Anaesthetic/interventional techniques. In: Davies A. (Ed). Cancer-related bone pain (2007), Davies, Oxford 85-97
19. Fine P.G., and Busch M.A. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Sympt Manage 16 (1998) 179-183
20. Foley K.M. Acute and chronic cancer pain syndromes. In: Doyle D., Hanks G., Cherny N., and Calman K. (Eds). Oxford textbook of palliative medicine. 3rd ed. (2004), Oxford University Press, Oxford 298-316
21. Fortner B.V., Okon T.A., and Portenoy R.K. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3 (2002) 38-44
22. Fortner B.V., Demarco G., Irving G., Ashley J., Keppler G., Chavez J., et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Sympt Manage 25 (2003) 9-18
23. Gannon C., and Davies A. Non-opioid drugs. In: Davies A. (Ed). Cancer-related breakthrough pain (2006), Oxford University Press, Oxford 83-96
24. Gómez-Batiste X., Madrid F., Moreno F., Gracia A., Trelis J., Nabal M., et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Sympt Manage 24 (2002) 45-52
25. Hanks G.W., de Conno F., Cherny N., Hanna M., Kalso E., McQuay H.J., et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84 (2001) 587-593
26. Harbour R., and Miller J. A new system for grading recommendations in evidence based guidelines. Br Med J 323 (2001) 334-336
27. Hwang S.S., Chang V.T., and Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 101 (2003) 55-64
28. Jacox A, Carr DB, Payne R, Berde CB, Breitbart W, Cain JM, et al. Management of cancer pain. Rockville: Agency for Health Care Policy and Research; 1994.
29. Kalso E., Heiskanen T., Rantio M., Rosenberg P.H., and Vainio A. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 67 (1996) 443-449
30. Laverty D., and Davies A. Assessment. In: Davies A. (Ed). Cancer-related breakthrough pain (2006), Oxford University Press, Oxford 23-30
31. Lussier D., and Portenoy R.K. Adjuvant analgesics in pain management. In: Doyle D., Hanks G., Cherny N., and Calman K. (Eds). Oxford textbook of palliative medicine. 3rd ed. (2004), Oxford University Press, Oxford 349-378
32. Mercadante S., and Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24 (1998) 425-432
33. Mercadante S., Sapio M., and Villari P. Suprascapular nerve block by catheter for breakthrough shoulder cancer pain. Reg Anesth 20 (1995) 343-346
34. Mercadante S., Radbruch L., Caraceni A., Cherny N., Kaasa S., Nauck F., et al. Episodic (breakthrough) pain. Consensus conference of an Expert Working Group of the European Association for Palliative Care. Cancer 94 (2002) 832-839
35. Mercadante S., Villari P., Ferrera P., Bianchi M., and Casuccio A. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Sympt Manage 27 (2004) 352-359
36. Mercadante S., Villari P., Ferrera P., and Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Sympt Manage 28 (2004) 505-510
37. Mercadante S., Villari P., Ferrera P., Porzio G., Aielli F., Verna L., et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Sympt Manage 32 (2006) 175-179
38. Parlow J.L., Milne B., Tod D.A., Stewart G.I., Griffiths J.M., and Dudgeon D.J. Self-administered nitrous oxide for the management of incident pain in terminally ill patients: a blinded case series. Palliat Med 19 (2005) 3-8
39. Petzke F., Radbruch L., Zech D., Loick G., and Grond S. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Sympt Manage 17 (1999) 391-401
40. Portenoy R.K. Treatment of temporal variations in chronic cancer pain. Sem Oncol 5 Suppl. 16 (1997) S16-7-12
41. Portenoy R.K., and Hagen N.A. Breakthrough pain: definition, prevalence and characteristics. Pain 41 (1990) 273-281
42. Portenoy R.K., Payne R., Coluzzi P., Raschko J.W., Lyss A., Busch M.A., et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79 (1999) 303-312
43. Portenoy R.K., Payne D., and Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81 (1999) 129-134
44. Portenoy R.K., Forbes K., Lussier D., and Hanks G. Difficult pain problems: an integrated approach. In: Doyle D., Hanks G., Cherny N., and Calman K. (Eds). Oxford textbook of palliative medicine. 3rd ed. (2004), Oxford University Press, Oxford 438-458
45. Portenoy R.K., Taylor D., Messina J., and Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 22 (2006) 805-811
46. Ripamonti C., Fagnoni E., Campa T., Seregni E., Maccauro M., and Bombardieri E. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Supp Care Cancer 15 (2007) 339-342
47. Ripamonti C., Fagnoni E., Campa T., Giardina V., Brunelli C., Pigni A., et al. Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study. Supp Care in Cancer 15 (2007) 1177-1184
48. Skinner C., Thompson E., and Davies A. Clinical features. In: Davies A. (Ed). Cancer-related breakthrough pain (2006), Oxford University Press, Oxford 13-22
49. Slatkin N.E., Xie F., Messina J., and Segal T.J. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Supp Oncol 5 (2007) 327-334
50. Swanson G., Smith J., Bulich R., New P., and Shiffman R. Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: a report of 117 patients. J Clin Oncol 7 (1989) 1903-1908
51. Swanwick M., Haworth M., and Lennard R.F. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med 15 (2001) 9-18
52. Twycross R., Wilcock A., Charlesworth S., and Dickman A. Palliative care formulary. 2nd ed. (2002), Radcliffe Medical Press, Abingdon
53. Wagner J.C., Souders G.D., Coffman L.K., and Horvath J.L. Management of chronic cancer pain using a computerized ambulatory patient-controlled analgesia pump. Hosp Pharm 24 (1989) 639-644
54. World Health Organization (WHO). Cancer pain relief. 2nd ed. Geneva: World Health Organization; 1996.
55. Zeppetella G. Oral transmucosal opioid drugs. In: Davies A. (Ed). Cancer-related breakthrough pain (2006), Oxford University Press, Oxford 57-71
56. Zeppetella G., O'Doherty C.A., and Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Sympt Manage 20 (2000) 87-92
57. Zeppetella G., and Ribeiro M.D. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother 4 (2003) 493-502
58. Zeppetella G., and Ribeiro M.D. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 1 (2006) CD004311